Prosensa Reports Initial Findings from Further Clinical Data Analyses of Drisapersen for Treatment of Duchenne Muscular Dystrophy

Prosensa Holding (NASDAQ: RNA ) today announced initial findings from further analyses from the aggregate data from the clinical development program of drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD)."We are encouraged by these results that suggest that treating earlier in the disease and treating longer shows a delay in the progression